- Home Prices Decline Further In Most Parts of US
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- Credit Card Firms Squeeze Customers as Rules Loom
- 'Thriller' Art: Warhol's Jackson Work Could Net $700,000
- Health Reform Does Little to Contains Costs: Analysts
- Ponzi Proceeds: Bidding on Madoff's Toys
- Trustee Seeks Billions for Madoff Investors
- Quiz: Do You Know Your Coca-Cola Myths?
- New Lows for Stocks Next Year: Equities Bear
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Passive Job Search Strategies
- Back Off, Regulators!
- America Is On Sale
- Warren Buffett and the Crisis: 'Brilliant Moves Interspersed with Some Surprising Errors'
- Schork Oil Outlook: More Strength in Crude
MOST SHARED
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- AIG Moving Toward Repaying Bailout: Moody's
- Home Prices Sank Further In Most Parts of US in 3rd Quarter
- Health-Care Reform Does Little To Contain Costs: Analysts
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
- News Corp. May Pull Content From Google Searches
- Pociask: In The Electronics War Does The Consumer Really Win?
- Trader Tax Sound Off
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
Text Size 
Did Martha Stewart miss out on a big payday on ImClone stock?
 |
Frank Franklin Ii / AP |
Bristol-Myers Squibb's [BMY
Loading...
()
] proposal to buy ImClone Systems [IMCL
Loading...
()
] for $4.5 billion brings back memories of the 2002 insider trading scandal that landed the domestic diva in jail and made ImClone a household word.
Stewart, who sold her ImClone stock in 2001—allegedly on a tip from ImClone founder Sam Waksal—got $58.43 a share, or a total of $229,513. She ended up being convicted in 2004 of lying to federal prosecutors about the circumstances surrounding the sale and spent five months in prison.
Now, Bristol-Myers Squibb is offering $60 for ImClone, so if Stewart had held onto her stock, she would've made a paltry $6,000 more seven years later.
But if she had waited until June 2004, when ImClone shares rose as high as $87, the payout would have been $112,223 more.
Stewart sold her stock allegedly on worries that the Food and Drug Administration was going to reject Erbitux, ImClone's colon cancer drug. Ironically, ImClone recently received positive reviews for the drug's efficacy on colon cancer and head and neck cancer. It is in the late stage of testing its effects on pancreatic cancer and may soon file with the FDA to investigate its effects on lung cancer.
What's more, former CEO Sam Waksal, who pleaded guilty to six criminal charges of perjury, securities fraud, bank fraud and obstruction of justice in August 2002, finishes his seven years and three months in prison next week.
Print
Email
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- What’s powering your microwave, fridge and computer? Part of it is fuel from Russian nuclear weapons. The NYT reports.
- With prices well below peak, gems could add some sparkle to your investments.
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.
Data is a real-time snapshot *Data is delayed at least 15 minutes